alprazolam

alprazolam
Name	Alprazolam
Tradename	Xanax, Niravam, Alprax, others
Routes of administration	Oral
Bioavailability	80–90%
Protein bound	80%
Metabolism	Hepatic (CYP3A4)
Elimination half-life	6–27 hours
Excretion	Urine
Cas number	28981-97-7
Atc prefix	N05
Atc suffix	BA12
Chemical formula	C17H13ClN4

alprazolam

Alprazolam is a short-acting triazolobenzodiazepine prescribed primarily for anxiety and panic disorders. It was developed and marketed in the late 20th century and has been widely used in outpatient psychiatry, primary care, and emergency medicine. Major manufacturers, regulatory agencies, academic centers, and patient advocacy groups have debated its role relative to other agents in guidelines and formularies.

Medical uses

Alprazolam is indicated for acute management of panic disorder, generalized anxiety disorder (GAD), and related conditions in treatment guidelines from organizations such as the American Psychiatric Association, National Institute for Health and Care Excellence, and various national formularies. Clinicians in settings at Mayo Clinic, Massachusetts General Hospital, and community clinics often choose alprazolam for short-term relief of severe anxiety and panic attacks, while specialists at institutions like Johns Hopkins Hospital, Cleveland Clinic, and Mount Sinai Health System may prefer longer-term strategies emphasizing psychotherapy from centers such as Menninger Clinic or pharmacotherapy alternatives like selective serotonin reuptake inhibitors endorsed by the World Health Organization and the Centers for Disease Control and Prevention. Emergency departments at hospitals like Bellevue Hospital Center and Royal London Hospital sometimes use rapid-acting agents for acute agitation, comparing alprazolam to agents studied at Harvard Medical School and University of Oxford.

Pharmacology

Alprazolam modulates the gamma-aminobutyric acid (GABA) system via benzodiazepine-binding sites on GABA-A receptors, a mechanism investigated by research groups at National Institutes of Health, Salk Institute, and university laboratories such as University of California, San Francisco and Columbia University. Metabolism is mediated primarily by the cytochrome P450 enzyme CYP3A4, with pharmacokinetic interactions studied by teams at Food and Drug Administration, European Medicines Agency, and academic pharmacology departments at Stanford University and University of Cambridge. Drug interaction case reports from hospitals like Toronto General Hospital and research published from Karolinska Institutet describe effects when coadministered with inhibitors such as ketoconazole studied at University of Sydney or inducers like rifampicin reported by investigators at Imperial College London. Structural and binding studies involve collaborators at Massachusetts Institute of Technology, ETH Zurich, and Max Planck Society.

Adverse effects and safety

Common adverse effects noted in product labeling and pharmacovigilance reports from agencies like the FDA and European Medicines Agency include sedation, dizziness, and cognitive impairment, with case series reported by academic centers such as UCLA, Yale School of Medicine, and University of Toronto. Safety advisories referencing populations at higher risk come from institutions including Veterans Affairs, American Geriatrics Society, and pediatric hospitals like Great Ormond Street Hospital. Reports of respiratory depression in combination with opioids prompted alerts from the Substance Abuse and Mental Health Services Administration and studies from emergency medicine groups at Johns Hopkins Hospital and St Thomas' Hospital. Drug safety surveillance networks coordinated by WHO and national pharmacovigilance centers have documented adverse events and black box warnings in collaboration with regulatory bodies in Canada, Australia, and Japan.

Dependence, withdrawal, and abuse potential

Dependence and withdrawal syndromes have been characterized in clinical series from addiction treatment centers such as Hazelden Betty Ford Foundation, American Addiction Centers, and university units at Columbia University Medical Center and University College London. Withdrawal symptoms, including seizures and rebound anxiety, were described in case reports from psychiatric hospitals like Bellevue Hospital Center and research from McMaster University and University of Melbourne. Epidemiological analyses by agencies including the National Institute on Drug Abuse and public health departments in New York City and London report patterns of nonmedical use and diversion, comparing alprazolam to other controlled substances monitored by the International Narcotics Control Board and national law enforcement agencies such as the Royal Canadian Mounted Police.

History and society

Alprazolam was developed by pharmaceutical research teams at Upjohn (later part of Pfizer) and introduced to markets in the 1980s amid contemporaneous launches of other psychotropics by companies such as Roche, Eli Lilly and Company, and GlaxoSmithKline. Its social and medical impact has been analyzed in health policy research from Harvard School of Public Health, London School of Hygiene & Tropical Medicine, and think tanks including the Kaiser Family Foundation. Cultural references and reporting have appeared in media outlets like The New York Times, The Guardian, BBC News, and investigative journalism by organizations such as ProPublica examining prescribing patterns and pharmaceutical marketing.

Legal status and regulation

Alprazolam is scheduled as a controlled substance in many jurisdictions, regulated by national agencies such as the Drug Enforcement Administration in the United States, the Home Office in the United Kingdom, and the Therapeutic Goods Administration in Australia. International scheduling and control measures are overseen by bodies including the World Health Organization and the International Narcotics Control Board, while national legislation and prescription monitoring programs operate through agencies like the Centers for Medicare & Medicaid Services, state health departments, and regulatory authorities in countries such as Germany, France, and Brazil. Litigation and regulatory actions involving manufacturers have been recorded in courts such as the United States District Court for the District of Columbia and appellate decisions reported by legal institutions like the Supreme Court of Canada.

Category:Benzodiazepines